PHIO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.3M
+2.4%
4.2M
+64.4%
2.5M
+1.2%
2.5M
+8.5%
2.3M
R&D
3.1M
+10.3%
2.8M
+89.1%
1.5M
+25.1%
1.2M
+10.0%
1.1M
SG&A
1.2M
-13.7%
1.4M
+30.0%
1.1M
-20.2%
1.3M
+7.2%
1.2M
Operating Income
-4268000
-2.4%
-4167000
-64.4%
-2534000
-1.2%
-2505000
-8.5%
-2309000
EBITDA
-4267000
-2.4%
-4166000
-64.5%
-2533000
-1.2%
-2503000
-8.4%
-2309000
Net Income
-4138000
-3.4%
-4003000
-68.8%
-2371000
+0.9%
-2392000
-10.4%
-2166000
EPS (Basic)
$-0.36
-5.9%
$-0.34
-36.0%
$-0.25
+43.2%
$-0.44
+2.2%
$-0.45
EPS (Diluted)
$-0.36
-5.9%
$-0.34
-36.0%
$-0.25
+43.2%
$-0.44
+2.2%
$-0.45
Shares (Diluted)
11.6M
+0.0%
11.6M
+24.0%
9.4M
+71.3%
5.5M
+14.1%
4.8M
Phio Pharmaceuticals (PHIO) โ€” Financials